Related Experiment Videos
[Clinical and pharmacokinetic evaluations of ceftizoxime suppositories in children]
Insights
Ceftizoxime suppository (CZX-S) offers a safe and effective alternative for pediatric bacterial infections, showing good efficacy and minimal side effects. This antibiotic suppository provides a convenient option for mild to moderate infections.
Area of Science:
- Pharmacology
- Pediatric Infectious Diseases
- Drug Delivery Systems
Context:
- Ceftizoxime is a third-generation cephalosporin antibiotic.
- Pediatric patients often require alternative antibiotic administration routes due to challenges with oral or intravenous delivery.
- Suppository formulations can offer advantages in patient compliance and ease of administration.
Purpose:
- To evaluate the safety, clinical efficacy, and pharmacokinetics of ceftizoxime suppository (CZX-S) in pediatric patients.
- To compare the bioavailability of CZX-S with intramuscular ceftizoxime.
- To assess the effectiveness of CZX-S in treating various pediatric bacterial infections.
Summary:
- Ceftizoxime suppository (CZX-S) demonstrated a Cmax of 4.8-9.5 µg/ml within 15-30 minutes, with a serum half-life of 0.93 hours.
- Bioavailability of CZX-S was approximately one-third compared to intramuscular administration.
- CZX-S was effective in 26 bacterial infections (e.g., pharyngitis, pneumonia, UTIs), with 95% eradication of causative organisms. Mild diarrhea (17%) was the only observed side effect.
Impact:
- Ceftizoxime suppository (CZX-S) presents a viable alternative to oral and injectable antibiotics for treating mild to moderate pediatric bacterial infections.
- The study supports CZX-S as a potentially valuable option for improving antibiotic accessibility and adherence in pediatric care.
- Findings suggest CZX-S can effectively manage common pediatric bacterial infections with a favorable safety profile.
Abstract:
Ceftizoxime suppository (CZX-S) was evaluated for its safety, clinical efficacy and pharmacokinetics in pediatric patients. The Cmax, 4.8 to 9.5 micrograms/ml, was obtained 15 to 30 minutes after administration of CZX-S, and the serum half-life was 0.93 hour. Cross-over comparison with intramuscular CZX in a child showed approximately one-third bioavailability of the suppository against intramuscular injection. CZX-S was effective in all the 26 bacterial infections including acute pharyngitis, pneumonia, soft tissue infection, and urinary tract infections. The causative organisms were eradicated in 95%. Mild diarrhea (17%) was the only side effect observed in the study. The data suggest that CZX-S is an excellent alternative to oral and injectable antibiotics for the treatment of mild to moderate bacterial infections due to the susceptible organisms.